Yarrow Bioscience details CDO stock options
Lori Payton, Chief Development Officer of Yarrow Bioscience, Inc., reports holding a stock option covering 175639.0000 shares of Issuer Common Stock.
Rhea-AI Filing Summary
Lori Payton, Chief Development Officer of Yarrow Bioscience, Inc., reports holding a stock option covering 175639.0000 shares of Issuer Common Stock. The option carries a $6.1900 exercise price and expires on 2036-01-30, held as a direct derivative position.
These options were received in a merger in which a wholly owned subsidiary of VYNE Therapeutics Inc. merged into Yarrow Bioscience, after which VYNE changed its name to Yarrow Bioscience, Inc. One quarter of this option is scheduled to vest on 2027-01-02, with the remaining three quarters vesting in equal monthly installments over the following three years, subject to Payton’s continued service.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
Payton Lori
Role
Chief Development Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Stock Option (Right to Buy) F1, F2, F3 | -- | -- | -- |
Holdings After Transaction:
Stock Option (Right to Buy) — 175,639 contracts (Direct)
Footnotes (3)
- F1. Effective as of July 27, 2026 (the "Effective Time"), a wholly owned subsidiary of VYNE Therapeutics Inc. ("VYNE") merged with and into Yarrow Bioscience, Inc. ("Yarrow") with Yarrow continuing as a wholly owned subsidiary of VYNE and the surviving corporation of the merger (the "Merger") under the name "Yarrow Bioscience Operating Company Corp." In connection with the completion of the Merger, VYNE changed its name to "Yarrow Bioscience, Inc." (hereinafter, the "Issuer").
- F2. Represents options to purchase shares of common stock, par value $0.0001, of the Issuer ("Issuer Common Stock") received by the Reporting Person in the Merger in exchange for options to purchase shares of common stock of Yarrow held by the Reporting Person prior to the Merger. At the Effective Time, the Issuer assumed each such Yarrow option, whether vested or unvested, and converted it into an option to purchase shares of Issuer Common Stock on the same terms and conditions as were in effect immediately prior to the Effective Time.
- F3. This option represents a right to purchase 175,639 shares of Issuer Common Stock, one quarter of which will vest on January 2, 2027, with the remaining three quarters vesting in equal monthly installments over the following three years, subject to the Reporting Person's continued service to the Issuer on each such vesting date.
Key Figures
Underlying option shares: 175639.0000 shares
Exercise price: $6.1900 per share
Option expiration date: 2036-01-30
+1 more
4 metrics
Underlying option shares
175639.0000 shares
Underlying Issuer Common Stock for Lori Payton's stock option holding
Exercise price
$6.1900 per share
Exercise price of the reported Stock Option (Right to Buy)
Option expiration date
2036-01-30
Expiration date of Lori Payton's reported stock option
Initial vesting date
2027-01-02
Date when one quarter of the option is scheduled to vest
Key Terms
Effective Time, surviving corporation, Issuer Common Stock, vesting
4 terms
Effective Time regulatory
"Effective as of July 27, 2026 (the "Effective Time"), a wholly owned subsidiary"
The exact clock time when a regulatory filing, approval, or corporate action formally becomes legally active; from that moment the change is binding and can be acted on. Investors care because the effective time marks when ownership, rights, trading rules, or new securities take effect — like a light switch turning on a contract or transaction — which determines when risks, benefits and market reactions begin.
surviving corporation regulatory
"Yarrow continuing as a wholly owned subsidiary of VYNE and the surviving corporation of the merger"
The surviving corporation is the company entity that continues to exist after a merger, consolidation, or similar reorganization; it absorbs the assets, liabilities, contracts, and business of the combining firms and remains on the legal books while the other entities cease to exist. For investors, it matters because ownership, shareholder rights, outstanding securities, and regulatory or listing obligations move into that single continuing company—think of it as the ship that all passengers board after two boats are joined together.
Issuer Common Stock financial
"Represents options to purchase shares of common stock, par value $0.0001, of the Issuer ("Issuer Common Stock")"
vesting financial
"one quarter of which will vest on January 2, 2027, with the remaining three quarters vesting in equal monthly installments"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What ownership does Lori Payton report in connection with VYNE (Yarrow Bioscience)?
Lori Payton reports a stock option giving her the right to purchase 175639.0000 shares of Issuer Common Stock. The option has a $6.1900 exercise price, expires on 2036-01-30, and is held directly as a derivative security.
What is the vesting schedule of Lori Payton’s reported stock option at VYNE?
The option vests over time: one quarter is scheduled to vest on January 2, 2027, and the remaining three quarters vest in equal monthly installments during the subsequent three years, conditioned on Payton’s continued service to Yarrow Bioscience.
How is the merger involving VYNE Therapeutics described in this ownership report?
A wholly owned subsidiary of VYNE Therapeutics Inc. merged with and into Yarrow Bioscience, with Yarrow as the surviving corporation and wholly owned subsidiary. In connection with this merger, VYNE changed its name to Yarrow Bioscience, Inc..
How did Lori Payton obtain the reported option position in Yarrow Bioscience (VYNE)?
The reported option reflects options received in the merger in exchange for Yarrow options previously held by Payton. At the effective time, Yarrow options were assumed and converted into options to purchase Issuer Common Stock on the same terms and conditions as before.
What is Lori Payton’s role at Yarrow Bioscience, Inc. (VYNE) according to this filing?
Lori Payton is reported as an officer, serving as the company’s Chief Development Officer. The filing connects her executive role with her derivative ownership through stock options over Issuer Common Stock following the merger and name change.
AI-generated analysis. How Rhea-AI works. Not financial advice.
